Lung Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Surgical and Radiation Therapies for High-Risk Early Lung Cancer
(Posted: 05/01/2012) - Patients with high-risk operable stage I lung cancer will be randomly assigned to undergo either sublobar resection, with or without brachytherapy, or stereotactic body radiation therapy.
Virus Therapy for Extensive-Stage Small Cell Lung Cancer
(Posted: 04/03/2012) - In this clinical trial, patients with extensive-stage small cell lung cancer who have received platinum-based chemotherapy will be randomly assigned to receive Seneca Valley virus-001 intravenously or an intravenous placebo.
Comparing Lung Cancer Targeted Therapies Based on KRAS Mutation Status
(Posted: 08/09/2011) - In this trial, doctors will test the KRAS mutation status of tumors in patients with advanced non-small cell lung cancer whose disease has progressed during or after chemotherapy; they will then randomly assign the patients to either AZD6244 plus erlotinib or either drug alone, depending on KRAS status of their tumors.
Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.
Comparing Second-Line Therapies for Advanced Lung Cancer
(Posted: 07/28/2009) - In this trial, patients with advanced non-small cell lung cancer that has recurred or progressed after initial chemotherapy will be tested for EGFR gene amplification and then randomly assigned to receive either pemetrexed or erlotinib.
(Posted: 05/01/2012) - Patients with high-risk operable stage I lung cancer will be randomly assigned to undergo either sublobar resection, with or without brachytherapy, or stereotactic body radiation therapy.
Virus Therapy for Extensive-Stage Small Cell Lung Cancer
(Posted: 04/03/2012) - In this clinical trial, patients with extensive-stage small cell lung cancer who have received platinum-based chemotherapy will be randomly assigned to receive Seneca Valley virus-001 intravenously or an intravenous placebo.
Comparing Lung Cancer Targeted Therapies Based on KRAS Mutation Status
(Posted: 08/09/2011) - In this trial, doctors will test the KRAS mutation status of tumors in patients with advanced non-small cell lung cancer whose disease has progressed during or after chemotherapy; they will then randomly assign the patients to either AZD6244 plus erlotinib or either drug alone, depending on KRAS status of their tumors.
Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.
Comparing Second-Line Therapies for Advanced Lung Cancer
(Posted: 07/28/2009) - In this trial, patients with advanced non-small cell lung cancer that has recurred or progressed after initial chemotherapy will be tested for EGFR gene amplification and then randomly assigned to receive either pemetrexed or erlotinib.
